Status:
COMPLETED
Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Background: Pioglitazone has been shown to have potent anti-inflammatory as well anti-atherosclerotic effects. However, the mechanisms by which pioglitazone exerts these effects are not clear. The inv...
Detailed Description
Pioglitazone has been shown to have potent anti-inflammatory as well anti-atherosclerotic effects. However, the mechanisms by which pioglitazone exerts these effects are not clear. We propose that tis...
Eligibility Criteria
Inclusion
- Fasting plasma Glucose- 126-270
- HbA1c \<10%
- Hematocrit \>34%
- Serum creatinine \<1.8mg/dl
- AST (aspartate aminotransferase) \< 2 times upper limit of normal
- ALT (Alanine aminotransferase) \< 2 time upper limit of normal
- Alkaline phosphatase \<2 times upper limit of normal
Exclusion
- Type 1 DM
- Fasting plasma glucose \>270 mg/dl
- Thiazolidinedione therapy
- Insulin therapy in last 3 months
- Congestive heart failure \> NYHA (New York Heart Association) class II
- History of dyspnoea on exertion
- Abnormal breath sounds
- EKG changes other than non-specific ST-T changes in the ECG (Electro-CardioGram) or LVH (Left Ventricular Hypertrophy)
- H/O Claudication
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01223196
Start Date
August 1 2009
End Date
December 1 2011
Last Update
January 11 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bartter Research Unit , ALM VA Hospital
San Antonio, Texas, United States, 78229